The lung microbiota in nontuberculous mycobacterial pulmonary disease

Background The role of bacterial microbiota in the pathogenesis of nontuberculous mycobacterial pulmonary disease (NTM-PD) is unclear. We aimed to compare the bacterial microbiome of disease-invaded lesions and non-invaded lung tissue from NTM-PD patients. Methods We analyzed lung tissues from 23 NTM-PD patients who underwent surgical lung resection. Lung tissues were collected in pairs from each patient, with one sample from a disease-involved site and the other from a non-involved site. Lung tissue microbiome libraries were constructed using 16S rRNA gene sequences (V3–V4 regions). Results Sixteen (70%) patients had Mycobacterium avium complex (MAC)-PD, and the remaining seven (30%) had Mycobacterium abscessus-PD. Compared to non-involved sites, involved sites showed greater species richness (ACE, Chao1, and Jackknife analyses, all p = 0.001); greater diversity on the Shannon index (p = 0.007); and genus-level differences (Jensen-Shannon, PERMANOVA p = 0.001). Analysis of taxonomic biomarkers using linear discriminant analysis (LDA) effect sizes (LEfSe) demonstrated that several genera, including Limnohabitans, Rahnella, Lachnospira, Flavobacterium, Megamonas, Gaiella, Subdoligranulum, Rheinheimera, Dorea, Collinsella, and Phascolarctobacterium, had significantly greater abundance in involved sites (LDA >3.00, p <0.05, and q <0.05). In contrast, Acinetobacter had significantly greater abundance at non-involved sites (LDA = 4.27, p<0.001, and q = 0.002). Several genera were differentially distributed between lung tissues from MAC-PD (n = 16) and M. abscessus-PD (n = 7), and between nodular bronchiectatic form (n = 12) and fibrocavitary form (n = 11) patients. However, there was no genus with a significant q-value. Conclusions We identified differential microbial distributions between disease-invaded and normal lung tissues from NTM-PD patients, and microbial diversity was significantly higher in disease-invaded tissues. Trial registration Clinical Trial registration number: NCT00970801.

[1]  M. Ranieri,et al.  The lower respiratory tract microbiome of critically ill patients with COVID-19 , 2021, Scientific Reports.

[2]  M. Qiu,et al.  Distinct tumor bacterial microbiome in lung adenocarcinomas manifested as radiological subsolid nodules , 2021, Translational oncology.

[3]  F. Velluzzi,et al.  Gut microbiota markers associated with obesity and overweight in Italian adults , 2021, Scientific Reports.

[4]  I. Khan,et al.  Gut microbiome dysbiosis and correlation with blood biomarkers in active-tuberculosis in endemic setting , 2021, PloS one.

[5]  S. Lee,et al.  The lung microbiota in Korean patients with non-tuberculous mycobacterial pulmonary disease , 2020, BMC microbiology.

[6]  Chieh-Chen Huang,et al.  Dynamics of the lung microbiome in intensive care patients with chronic obstructive pulmonary disease and community-acquired pneumonia , 2020, Scientific Reports.

[7]  J. Brożek,et al.  Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline , 2020, European Respiratory Journal.

[8]  L. Hoffman,et al.  Lung function and microbiota diversity in cystic fibrosis , 2020, Microbiome.

[9]  L. Falcón,et al.  Alveolar microbiota profile in patients with human pulmonary tuberculosis and interstitial pneumonia. , 2019, Microbial pathogenesis.

[10]  Yongfei Hu,et al.  The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients , 2019, Front. Cell. Infect. Microbiol..

[11]  T. Shim,et al.  The natural history of non-cavitary nodular bronchiectatic Mycobacterium avium complex lung disease. , 2019, Respiratory medicine.

[12]  W. Koh,et al.  Epidemiology of Nontuberculous Mycobacterial Infection, South Korea, 2007–2016 , 2019, Emerging infectious diseases.

[13]  Karan P. Singh,et al.  Microbiome Diversity in Sputum of Nontuberculous Mycobacteria Infected Women with a History of Breast Cancer. , 2019, Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology.

[14]  M. Moffatt,et al.  Profiling mycobacterial communities in pulmonary nontuberculous mycobacterial disease , 2018, PloS one.

[15]  C. Ki,et al.  Development of Macrolide Resistance and Reinfection in Refractory Mycobacterium avium Complex Lung Disease , 2018, American journal of respiratory and critical care medicine.

[16]  J. Clemente,et al.  Evaluation of the airway microbiome in nontuberculous mycobacteria disease , 2018, European Respiratory Journal.

[17]  P. Galan,et al.  Associations between dietary scores with asthma symptoms and asthma control in adults , 2018, European Respiratory Journal.

[18]  Vineet K. Sharma,et al.  Gut microbiome contributes to impairment of immunity in pulmonary tuberculosis patients by alteration of butyrate and propionate producers , 2018, Environmental microbiology.

[19]  J. Yim,et al.  Treatment Outcomes of Mycobacterium avium Complex Lung Disease: A Systematic Review and Meta-analysis , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  C. Ki,et al.  Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype , 2017, European Respiratory Journal.

[21]  B. Methé,et al.  Microbiome in lung explants of idiopathic pulmonary fibrosis: a case–control study in patients with end-stage fibrosis , 2017, Thorax.

[22]  J. Chun,et al.  Introducing EzBioCloud: a taxonomically united database of 16S rRNA gene sequences and whole-genome assemblies , 2017, International journal of systematic and evolutionary microbiology.

[23]  T. Shim,et al.  Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course , 2017, European Respiratory Journal.

[24]  Tobias R Kollmann,et al.  Shifts in Lachnospira and Clostridium sp. in the 3-month stool microbiome are associated with preschool age asthma. , 2016, Clinical science.

[25]  D. O’Dwyer,et al.  The Lung Microbiome, Immunity, and the Pathogenesis of Chronic Lung Disease , 2016, The Journal of Immunology.

[26]  L. Raskin,et al.  Culture-Independent Identification of Nontuberculous Mycobacteria in Cystic Fibrosis Respiratory Samples , 2016, PloS one.

[27]  James R. Brown,et al.  Lung microbiome dynamics in COPD exacerbations , 2016, European Respiratory Journal.

[28]  Kazumasa Fukuda,et al.  Possible role of anaerobes in the pathogenesis of nontuberculous mycobacterial infection , 2015, Respirology.

[29]  B. Paster,et al.  The hidden ‘mycobacteriome’ of the human healthy oral cavity and upper respiratory tract , 2015, Journal of oral microbiology.

[30]  G. Rogers,et al.  The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. , 2014, The Lancet. Respiratory medicine.

[31]  J. Chun,et al.  Profiling bacterial community in upper respiratory tracts , 2014, BMC Infectious Diseases.

[32]  Meilan K. Han,et al.  Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. , 2014, The Lancet. Respiratory medicine.

[33]  Jesse R. Zaneveld,et al.  Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences , 2013, Nature Biotechnology.

[34]  F. Drobniewski,et al.  The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study , 2013, European Respiratory Journal.

[35]  G. Fantuzzi,et al.  Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes. , 2013, American journal of respiratory and critical care medicine.

[36]  A. Klindworth,et al.  Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies , 2012, Nucleic acids research.

[37]  S. Keshavjee,et al.  Pulmonary Bacterial Communities in Surgically Resected Noncystic Fibrosis Bronchiectasis Lungs Are Similar to Those in Cystic Fibrosis , 2012, Pulmonary medicine.

[38]  Kyle Bittinger,et al.  Topographical continuity of bacterial populations in the healthy human respiratory tract. , 2011, American journal of respiratory and critical care medicine.

[39]  C. Huttenhower,et al.  Metagenomic biomarker discovery and explanation , 2011, Genome Biology.

[40]  Pierre Taberlet,et al.  ITS as an environmental DNA barcode for fungi: an in silico approach reveals potential PCR biases , 2010, BMC Microbiology.

[41]  M. Raffeld,et al.  Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. , 2008, American journal of respiratory and critical care medicine.

[42]  R. Weinstein,et al.  Acinetobacter infection. , 2008, The New England journal of medicine.